Asthma Spacers Market

Asthma Spacers Market: Overview

The Asthma Spacers Market is valued at USD 2.3 Bn in 2026 and is projected to reach USD 3.7 Bn, growing at a CAGR of 7% by 2033.The size of the Asthma Spacers market worldwide was estimated at USD 1,982.4 million in 2021, and it is anticipated to increase at a CAGR of 5.5%. One of the major factors affecting the growth of the studied market is the increasing prevalence of chronic respiratory disorders, more awareness of the benefits of spacers, and increased spending by public and commercial entities in R&D efforts for product innovation. With the prevalence of harmful environmental, occupational, and behavioral inhalational exposures, chronic respiratory problems are among the most prevalent non-communicable diseases worldwide. The World Health Organization (WHO) estimates that asthma killed 4,55,000 people and affected 262 million people in 2019. Such elements will probably increase the use of asthma spacers, which will help the market grow while it is being examined. Those who have asthma might need to use their inhalers daily. A spacer device makes it simpler to utilize an aerosol inhaler and aids in the medication's better lung absorption. As a result, the usage of asthma spacer devices is anticipated to expand in the future. It is thus likely to boost the growth of the asthma spacer market globally throughout the forecast period.

The top market players' strategic moves and introduce new products are also helping the market under study grow. For instance, Philip Morris also announced a plan to acquire Vectura in March 2021 for an enterprise value of USD 1.2 billion. The acquisition will hasten Philip Morris International's (PMIs) strategy beyond nicotine and increase its capacity for inhaled treatments product pipeline development. Thus, the studied market is anticipated to expand significantly throughout the forecast period due to new launches and acquisitions. As a result of the variables above, it is projected that the market under study will expand during the investigation.

Asthma Spacers Market: COVID-19 Impact

The COVID-19 situation is expected to lead the market for asthma spacers to expand even more quickly. In terms of future pandemic preparedness, the threat will also have a long-term impact on governing bodies and regulatory organizations. The need for asthma spacers has surged due to the increase of COVID-19 cases with respiratory symptoms, and many patients have experienced acute respiratory illness syndrome (ARDS). The high virus transmissibility serves as a solid justification for using asthma spacers. According to many nations, small-volume nebulizers (SVNs) should be phased out, and asthma spacers should be used instead. Additionally, COVID-19 poses a significant risk of serious disease for those with asthma (PWA). A significant portion of COVID-19 patients is asymptomatic, which has forced patients to use asthma spacers, favoring the market opportunity for these medications.

Asthma Spacers Market: Drivers

Rising Respiratory Disease Prevalence to Fuel Market Expansion

The rising prevalence of respiratory disorders, a major element fueling the expansion of the worldwide asthma spacer market, is the cause of the rising demand for asthma spacers. Increased asthma risk is associated with several variables, including allergic diseases, eczema and rhinitis (hay fever), urbanization, exposure to tobacco smoke, and viral respiratory infections. The World Health Organization (WHO) estimates that in 2019 asthma killed over 461,000 people and impacted nearly 262 million people. Inhalers are being used increasingly often to treat asthma symptoms. Most people cannot use inhalers efficiently because they need to take a deep breath just as the medication is about to be released. Spacers allow patients to take their prescriptions more successfully. As a result, the demand for asthma spacers is rising globally.

Growing Air Pollution is Likely to Increase Cases of Asthama, Driving Market’s Growth

Chronic respiratory disease, known as asthma, is characterized by varying airflow restriction, bronchial hyperresponsiveness, and airway inflammation. According to a study, air pollution seems harmful to asthma outcomes in adults and children. Children's exposure to secondhand smoke (SHS), nitrogen dioxide, and air pollution from vehicles are all significant risk factors for the development of asthma. A connection between air pollution and the onset of adult asthma has not yet been proven. Exposure to outdoor pollutants can cause exacerbations of asthma, symptoms, and impaired lung function. Asthma, a serious and potentially fatal chronic respiratory condition that affects more than 23 million Americans, has long been linked to exposure to air pollution in the US. Air pollution may exacerbate asthma symptoms and precipitate asthma attacks. Pollution poses a particular threat to asthma children, affecting an estimated six million children in the United States. Thus, with the growing exposure to air pollution, the cases of asthma will rise, increasing the product demand.

Asthma Spacers Market: Restraints

Lack of Understanding and High Cost of Asthma Medicines to Limit Market Growth

Although asthma is becoming more common worldwide, including in developed markets like North America and growing countries like Asia, some barriers prevent the widespread use of these treatments. Higher prices for asthma inhalers, frequently seen as the primary treatment for asthma, are one of the main issues limiting the market's growth. A significant barrier to market expansion and high medication costs is consumers' lack of awareness or information regarding the proper use of such products. Technology has advanced, but nurses, doctors, and therapists still don't fully understand how to use and administer devices. Lack of expert advice regarding the use of a product or equipment to patients or practitioners may limit product uptake and the expansion of the target market.

Asthma Spacers Market: Segment Overview

With Improved Method of Drug Delivery, Demand for Aerochmaber Spacer to Grow

An aero chamber spacer is used in conjunction with a metered-dose inhaler to enhance the effects of medication. Aero chamber spacer use is fueled by the rising use of inhalers and the prevalence of respiratory disorders, ultimately fueling segment expansion. A plastic tube, a valve, a mouthpiece, and a soft, sealed end to accommodate the metered-dose inhaler make up the aero chamber spacer. The aero chamber allows it to administer medication to the lungs' tiny airways. This process catalyzes the efficiency of the medication. Metered-dose inhaler (MDI) is a useful approach for inhalation treatment due to its portability, effectiveness, and superior ergonomics. An aero chamber spacer extends the time patients have to use the inhaler, simplifying the procedure. It takes less coordination to press the inhales while breathing the medication. Additionally, aero chamber spacers lengthen the time it takes the inhaler to deliver medication and reduce the possibility of adverse effects like mouth thrush. As a result, increasing numbers of patients are choosing it.

Clinics & Hospitals Segment to Dominate Market due to Improved Care of Asthama in Hospital Setting

It is anticipated that the Clinics & Hospitals segment will hold the greatest market share throughout the projected period. One of the main factors contributing to the Clinics & Hospitals segment's dominance is that many medicines used to treat asthma can only be prescribed in hospital settings by qualified medical personnel. This enables the accurate and safe administration of crucial therapeutics—some of which must be provided through subcutaneous injections—and the proper adherence to the recommended course of therapy. Such adequate and proper treatment frequently enables the efficient control of asthma symptoms. Asthma causes 439,000 hospital admissions each year and 1.3 million visits to emergency rooms, which is anticipated to stimulate segmental expansion throughout the anticipated period.

Asthma Spacers Market: Regional Landscape

North America to Acquire Major Market Share due to Increased Cases of Respiratory Disorders

The market for asthma spacers in North America held the greatest revenue share in the global market in 2020. Major factors driving the regional market revenue growth include the rising prevalence of chronic respiratory diseases like asthma, COPD, and lung cancer, the growing availability of high-end, technologically advanced inhalers, spacers, and other respiratory devices, rising investments in R&D activities to develop more advanced respiratory devices, and the presence of cutting-edge healthcare infrastructure in the region. Over 25 million Americans will be affected by asthma in 2020, according to the Asthma and Allergy Foundation of America (AAFA). Asthma affected roughly 20 million American individuals aged 18 and older in 2019. On average, 11 Americans lose their lives to asthma every day. As a result, the usage of asthma spacer devices is anticipated to expand in the future. It is thus likely to boost the growth of the asthma spacer market globally throughout the forecast period.

The market for asthma spacers in the US is expanding due to important product approvals, a high concentration of market participants, or manufacturer presence in the country. For instance, Cipla Limited stated in April 2020 that it's Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation had gained final clearance. Always use an attachment with an inhaler, such as an aerosol 90mcg (base)/actuation with a spacer or holding chamber. Therefore, the studied market will be projected to develop in the North America Region due to the causes above.

During the forecast period, the Asia Pacific asthma spacers market is anticipated to grow at a considerable CAGR. In the upcoming years, the market in the region is expected to be driven by a sizable number of people with asthma whose symptoms are poorly controlled and by an increase in health care spending. Asthma was a condition in 8.0% of South Asians and 4.6% of Chinese people. Additionally, the low cost of manufacturing in China and India has led to an increase in the number of production facilities in the two nations, drawing important players from around the globe to the area. The main driver of rising sales and demand for spacers in the Asia Pacific region is consumer awareness of the products on the market. This, along with an increase in industry player mergers and acquisitions, is projected to boost product sales in nations like China, India, and other nations.

Global Asthma Spacers Market: Competitive Landscape

In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced that the US Food and Drug Administration (FDA) had approved Trelegy Ellipta (fluticasone furoate /umeclidinium /vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients aged 18 years and older, extending its existing authorization for use in people with chronic obstructive pulmonary disease (COPD). With this approval, Trelegy becomes the first and only single inhaler triple therapy offered to patients in the US in a simple once-daily inhalation for the maintenance treatment of COPD and asthma. In April 2020, Adherium Limited, a market leader in digital inhaled device adherence, remote monitoring, and data management systems, inked a head terms sales agreement with Monaghan Medical Corporation, Trudell Medical Limited's US affiliate. Monaghan has a well-established and thorough sales team that works across the United States to assist the commercialization of AeroChamber, Aerobika, and AeroEclipse devices.          

Few of the players in the Asthma Spacers Market include 

• 3M (including AeroChamber)
• Trudell Medical International
• PARI GmbH
• Omron Healthcare
• Vortex Medical (owned by Teleflex)
• Teleflex Incorporated
• Respironics (Philips)
• Drive Medical
• Smiths Medical (ICU Medical)
• NHS Supply Chain / NHS Brands
• CareFusion (BD)
• AeroVentures, LLC
• Vitalograph
• SunLife Science Co., Ltd.
• FineMed Co., Ltd.

Global Asthma Spacers Market Segmentation is Described Below:

By Type

• Aerochamber
• Optichamber
• Volumatic
• InspirEase

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Optical Stores
• Online Pharmacies

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa